These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 8625310)

  • 1. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins.
    Taniguchi K; Kohno K; Kawanami K; Wada M; Kanematsu T; Kuwano M
    Cancer Res; 1996 May; 56(10):2348-54. PubMed ID: 8625310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus.
    Yamashita Y; Kawada S; Fujii N; Nakano H
    Biochemistry; 1991 Jun; 30(24):5838-45. PubMed ID: 1646001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.
    Kotoh S; Naito S; Yokomizo A; Kumazawa J; Asakuno K; Kohno K; Kuwano M
    Cancer Res; 1994 Jun; 54(12):3248-52. PubMed ID: 8205547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of a CPT-11-resistant human ovarian cancer cell line.
    Kijima T; Kubota N; Nishio K
    Anticancer Res; 1994; 14(3A):799-803. PubMed ID: 8074481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
    Goldwasser F; Bae I; Fornace AJ; Pommier Y
    Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
    Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
    Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
    Kohara H; Tabata M; Kiura K; Ueoka H; Kawata K; Chikamori M; Aoe K; Chikamori K; Matsushita A; Harada M
    Clin Cancer Res; 2002 Jan; 8(1):287-92. PubMed ID: 11801571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
    Minagawa Y; Kigawa J; Itamochi H; Terakawa N
    Hum Cell; 2001 Sep; 14(3):237-43. PubMed ID: 11774743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance].
    Furukawa M; Harada T; Tanaka T; Kuwano M
    Nihon Rinsho; 1997 May; 55(5):1096-102. PubMed ID: 9155159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
    Prost S; Riou G
    Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
    Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
    Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between the formation of cleavable complex with topoisomerase I and growth-inhibitory activity for saintopin-type antibiotics.
    Fujii N; Yamashita Y; Mizukami T; Nakano H
    Mol Pharmacol; 1997 Feb; 51(2):269-76. PubMed ID: 9203632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced expression of the DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells.
    Matsuo K; Kohno K; Sato S; Uchiumi T; Tanimura H; Yamada Y; Kuwano M
    Cancer Res; 1993 Mar; 53(5):1085-90. PubMed ID: 8382554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.
    Yanase K; Sugimoto Y; Tsukahara S; Oh-Hara T; Andoh T; Tsuruo T
    Jpn J Cancer Res; 2000 May; 91(5):551-9. PubMed ID: 10835501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase II inhibitors fail to induce chromosome-type aberrations in etoposide-resistant cells: evidence for essential contribution of the cleavable complex formation to the induction of chromosome-type aberrations.
    Suzuki H; Tarumoto Y; Ohsawa M
    Mutagenesis; 1997 Jan; 12(1):29-33. PubMed ID: 9025094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
    Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
    Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro.
    Stahl M; Kasimir-Bauer S; Harstrick A
    Anticancer Drugs; 1997 Aug; 8(7):671-6. PubMed ID: 9311443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined modalities of resistance in etoposide-resistant human KB cell lines.
    Ferguson PJ; Fisher MH; Stephenson J; Li DH; Zhou BS; Cheng YC
    Cancer Res; 1988 Nov; 48(21):5956-64. PubMed ID: 2844393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
    Utsugi T; Aoyagi K; Asao T; Okazaki S; Aoyagi Y; Sano M; Wierzba K; Yamada Y
    Jpn J Cancer Res; 1997 Oct; 88(10):992-1002. PubMed ID: 9414662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.